THE INCIDENCE OF PROSTATE CANCER IN A SCREENING POPULATION WITH A SERUM PROSTATE SPECIFIC ANTIGEN BETWEEN 2.5 AND 4.0 NG./ML.: RELATION TO BIOPSY STRATEGY
- 1 March 2001
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 165 (3) , 757-760
- https://doi.org/10.1016/s0022-5347(05)66519-6
Abstract
It has recently been suggested that the diagnostic threshold for the prostate specific antigen (PSA) assay be lowered to enhance prostate cancer detection. A 22% incidence of prostate cancer has been reported in men with PSA between 2.5 and 4.0 ng/ml. We designed a study to confirm this observation. Men who participated in our free early detection program and who had serum PSA between 2.5 and 4.0 ng/ml were asked to undergo prostate biopsy. Of 268 eligible men 151 (56%) agreed to participate in this free trial. All men underwent biopsy using an 11-core multisite directed biopsy scheme. All biopsy cores were color coded for location specificity and examined by 1 pathologist. Cancer was identified in 24.5% (37 of 151) of the men biopsied. The median age of men with cancer was 62 years (range 43 to 74). Conventional systematic sextant biopsies, which accounted for 6 of the 11 cores, detected 73.0% (27 of 37) of the cancers and the alternate site biopsies identified the remaining 10. Gleason score was 6 in 25 men, 3 + 4 in 5, 4 + 3 in 4 and 8 or greater in 3 (median Gleason score 6). There were 14 men who had 1 core positive for cancer, 9 had 2 and 14 had more than 2 (median number of positive cores 2). Of the 14 men with 1 positive core 11 had a less than 3 mm focus of cancer and 8 had only a positive alternate site biopsy. There were 11 cases of abnormal results on digital rectal examination, 5 of which were cancer, and 31 cases of abnormal results on ultrasonography, 13 of which were cancer. Median biological variability in PSA was +/-15% (range 0.4% to 440.0%). We found a significant incidence of cancer (24.5%, 37 of 51) in men with serum PSA between 2.5 and 4.0 ng/ml. In our study 67.6% of the detected cancers were significant based on the biopsy data. If the PSA threshold is lowered the conventional systematic sextant technique may be preferable to an extended strategy.Keywords
This publication has 15 references indexed in Scilit:
- PROSTATE CANCER DETECTION AT LOW PROSTATE SPECIFIC ANTIGENJournal of Urology, 2000
- A COMPARATIVE ANALYSIS OF SEXTANT AND AN EXTENDED 11-CORE MULTISITE DIRECTED BIOPSY STRATEGYJournal of Urology, 2000
- Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurementsJAMA, 1997
- Comparative Analysis of Prostate Specific Antigen and its Indexes in the Detection of Prostate CancerJournal of Urology, 1996
- European randomized study of screening for prostate cancer—The Rotterdam pilot studiesInternational Journal of Cancer, 1996
- Tumor Volume and Prostate Specific Antigen: Implications for Early Detection and Defining a Window of CurabilityJournal of Urology, 1995
- Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcomeUrology, 1995
- Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference rangesJAMA, 1993
- Prostate‐specific antigen lewels in 1695 men without evidence of prostate cancer: Findings of the American cancer society national prostate cancer detection projectCancer, 1992
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991